Not applicableStudy completedNCT01584141What this trial is testingStudy of Lymphoma in AsiaWho this might be right forLymphoma, FollicularLymphoma, Non-HodgkinMultiple Myleoma+3 more National Cancer Institute (NCI) 13,433
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06880601What this trial is testingTeclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple MyelomaWho this might be right forMultiple MyleomaMultiple Myeloma in RelapseMultiple Myeloma Refractory Gruppo Italiano Malattie EMatologiche dell'Adulto 52
Testing effectiveness (Phase 2)Ended earlyNCT00074490What this trial is testingDonor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph CancersWho this might be right forLymphomaLeukemiaMyeloproliferative Disorders+2 more National Cancer Institute (NCI) 442
Testing effectiveness (Phase 2)Looking for participantsNCT06952075What this trial is testingGR1803 Injection in Patients With RRMMWho this might be right forMultiple Myleoma Genrix (Shanghai) Biopharmaceutical Co., Ltd. 30
Large-scale testing (Phase 3)Looking for participantsNCT05645107What this trial is testingEvaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin LymphomaWho this might be right forHypogammaglobulinemiaBacterial InfectionsB-cell Chronic Lymphocytic Leukemia+2 more Grifols Therapeutics LLC 386
Very early researchLooking for participantsNCT06663046What this trial is testingUniversal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple MyelomaWho this might be right forMultiple MyleomaRefractory and Relapsed Multiple Myeloma Wondercel Biotech (ShenZhen) 30